ORIGINAL ARTICLE

The effect of zolpidem on cognitive function and postural control at high altitude

Pierre Bouzat[1,2,†], Guillaume Séchaud[1,3,†], Pierre Banco[1,3], Karen Davranche[4], Laurence Casini[5], Sébastien Baillieul[1,3], Pauline Manhes[1], Francesco Botrè[6,7], Monica Mazzarino[6], Xavier De la Torre[6], Paul Robach[3,8] and Samuel Verges[1,3,*]

[1]Intensive Care Unit, Grenoble Alpes University Hospital, Grenoble, France, [2]Grenoble Institute of Neurosciences, INSERM U836, Grenoble, France, [3]HP2 Laboratory, U1042, Grenoble Alpes University, INSERM, Grenoble, France, [4]Laboratoire de Psychologie Cognitive (LPC), UMR 7290, CNRS, Aix-Marseille Université, Marseille, France, [5]Laboratoire de Neurosciences Cognitives (LNC), UMR 7291, CNRS, Aix Marseille Université, FR 3C FR 3512, Marseille, France, [6]Laboratorio Antidoping, Federazione Medico Sportiva Italiana, Rome, Italy, [7]Department of Experimental Medicine, Sapienza University of Rome, Italy and [8]National school for mountain sports (ENSM), Chamonix, France

*Corresponding author. Samuel Verges, Laboratoire HP2 (INSERM U 1042), UM Sports Pathologies, Hôpital Sud, Avenue Kimberley, 38 434 Echirolles, France. Email: sverges@chu-grenoble.fr.

[†]Both authors share first authorship.

Abstract

Study Objectives: Sleep is altered at high altitude leading many mountaineers to use hypnotics in order to improve sleep efficiency. While after a full night at altitude the short-acting hypnotic zolpidem does not appear to alter cognitive function, residual adverse effects should be considered following early waking-up as performed by mountaineers. We hypothesized that zolpidem intake at high altitude would alter cognitive function 4 hours after drug intake.

Methods: In a randomized double-blind controlled cross-over study, 22 participants were evaluated during two nights at sea level and two nights at 3800 m, 4 hours after zolpidem (10 mg) or placebo intake at 10:00 pm. Polygraphic recording was performed until waking-up at 01:30 am. Sleep quality, sleepiness and symptoms of acute mountain sickness were assessed by questionnaires. Two cognitive tasks (Simon task and duration-production task) were performed at rest and during exercise and postural control was evaluated.

Results: Zolpidem increased reaction time in all conditions (zolpidem 407 ± 9 ms vs. placebo 380 ± 11 ms; $p < 0.001$) and error rate in incongruent trials only (10.2 ± 1.1% vs. 7.8 ± 0.8%; $p < 0.01$) in the Simon task and increased time perception variability ($p < 0.001$). Zolpidem also altered postural parameters (e.g. center of pressure area, zolpidem 236 ± 171.5 mm^2 vs. placebo 119.6 ± 59 mm^2; $p < 0.001$). Zolpidem did not affect apnea-hypopnea index and mean arterial oxygen saturation ($p > 0.05$) but increased sleep quality ($p < 0.001$). Zolpidem increased symptoms of acute mountain sickness and sleepiness ($p < 0.05$).

Conclusions: Acute zolpidem intake at high altitude alters cognitive functions and postural control during early wakening which may be deleterious for safety and performances of climbers.

Statement of Significance

Sleep is altered at high altitude leading many mountaineers to use hypnotics in order to improve sleep efficiency and recovery. To climb in adequate conditions, mountaineers generally wake up very early during the night. This study shows that zolpidem intake (10 mg at 10:00 pm) and early waking-up (01:30 am) at altitude are associated with significant alteration in cognitive and postural performances. These effects may have potential deleterious consequences on the safety and physical abilities of climbers using zolpidem during sojourn at high altitude.

Introduction

Periodic breathing related to central sleep apnea is the hallmark of sleep perturbations observed at high altitude, leading to sleep architecture alterations and increased daytime sleepiness [1, 2]. These disturbances are highly prevalent [3] and belong to symptoms characterizing acute mountain sickness (AMS, according to the Lake Louise Score [LLS]) [4]. To improve sleep at high altitude, hypnotics have been recommended [5] and mountaineers use these drugs to enhance sleep quality and recovery. In a recent study from our group investigating drug use at altitude [6], hypnotics were found prevalent (12.9%, including 8.4% of zolpidem) in the urines of mountaineers ascending Mont Blanc (Chamonix, France).

Zolpidem is a short-acting, non-benzodiazepine hypnotic that is widely used to treat insomnia [7]. Previous studies performed at high altitude suggested that zolpidem intake: (1) reduces symptoms of AMS without inducing cognitive alteration and (2) improves sleep quality, with no effect on nocturnal respiratory parameters [8–10]. However, these studies evaluated the residual effects of zolpidem about 8 hours after administration. Mountaineers at high altitude generally wake-up in the middle of the night to climb in the most appropriate conditions (temperature, risks of avalanche, etc). For instance in the mountain huts located on the main climbing routes to the Mont-Blanc [6], waking-up is scheduled at midnight or 01:00 am. Although zolpidem has a short half-life (1.5–2.4 hours) [11], previous results indicate significant residual effects up to 5 hours after drug intake at sea level with alterations in cognitive performances and car driving [12, 13]. Mountaineering requires full physical and cognitive (i.e. attention, decision making) capacities to ensure safety while climbing. To our knowledge, there is no available data on the residual effects of zolpidem at early wakening during a high altitude stay. Based on previous studies reporting significant alterations in cognitive [13, 14] and physical (e.g. impaired postural control [15, 16]) abilities 1.5 to 5 hours after zolpidem intake at sea level, the potential residual effects of zolpidem following early wakening (i.e. 4 hours after administration) at high altitude may represent a critical concern for climbers' safety.

The objective of this study was to assess the effects of zolpidem on (1) cognitive functions both at rest and during exercise (i.e. under dual-task condition mimicking a physical and cognitive demanding activity such as climbing) and (2) postural control assessed following early waking-up at high altitude. We hypothesized that zolpidem intake at high altitude would alter cognitive function both at rest and during exercise and postural control measured 4 hours after drug intake compared to zolpidem intake at sea level and placebo intake at high altitude.

Material and Methods

Study design

We conducted a randomized, controlled and double-blind study with a cross-over design (Figure 1). The ethics committee approved the design of the study (CPP Sud Est III, EudraCT n°2015-004512-38) and the study is recorded on clinicaltrials.gov (NCT02778659). Signed written informed consent was obtained for all the participants before inclusion. All experiments were conducted in the Grenoble University Hospital (sea level) and at the laboratory of Aiguille du midi (3800 m, Chamonix, France).

Eligible participants were assigned by electronic randomization to start with sea level or altitude condition first and then to take Zolpidem or placebo treatments (Figure 1). All participants and outcome assessors were unaware of treatment allocation for any subject. Methodological design was based on the CONSORT Statement [17].

Subject selection

Healthy participants were recruited based on a voluntary basis between June and November 2016 and were included if they: (1) were ≥18 and <60 years-old, (2) resided at low altitude (<1000 m of altitude) and were not acclimatized to high altitude at the time of the tests (defined as no sojourn above 2000 m over the past 2 months), and (3) were physically active with a maximum of two endurance activity sessions per week. For each female subject, all sessions were scheduled at the same period of her menstrual period. Exclusion criteria were any somatic or psychiatric disease, hypnotics consumption, zolpidem intolerance, history of severe AMS, extreme circadian typology (assessed by Horne and Ostberg questionnaire, <30 or >70 [18]), insomnia or sleepiness (Epworth questionnaire >10 [19] or Pittsburg questionnaire >5 [20]) and smoking.

Study protocol

After one familiarization session, participants performed four experimental sessions, two in Grenoble (sea level) and two at the Aiguille du Midi (at the top cable car station, 3800 m). Participants arrived at the Aiguille du Midi at 04:30 pm. All experimental sessions were organized according to the same protocol. Zolpidem oral administration was performed at 09:55 pm. After 3 hours and 30 minutes of sleep (at 01:30 am), participants were woken up and blood samples were collected. Then participants answered questionnaires and after a light standardized breakfast, postural evaluations were conducted. Cognitive tests started at 02:00 am and the experimentations ended at 03:15 am.

Cognitive performance

The cognitive tasks were performed by the participants seated on a cycle ergometer, equipped with two thumb response keys fixed on the top of the right and left handle grips, positioned in front of a screen positioned 1 m away. In each session, participants performed three blocks of each cognitive task, that is, a Simon task [21] and a duration-production task [22], presented alternately and in a counterbalanced order. Cognitive performance was first evaluated at rest and then while cycling at 50% of the subject estimated maximal aerobic power at sea level (calculated based on the Wasserman formula [23]) and at altitude (calculated as 80% of the normoxic maximal aerobic power [24]). Heart rate and arteriolar oxygen saturation (SpO_2) were continuously recorded (Nonin Onyx Oximeter, Plymouth, MN) during cognitive tasks at rest and during exercise.

Simon task. The Simon task is a choice reaction time task providing information about the ability of participants to resist prepotent but inappropriate responses. Participants are required to respond to the shape (or the color) of the stimulus according to a rule given by the experimenter and then ignore the location of the stimulus (on the right or the left of a central point) which

Figure 1. Flow diagram of the recruitment process and allocation of the participants.

triggers automatic response activation (for a review, see ref. [21]). The task includes two equiprobable and randomized trial types: the congruent trials (response ipsilateral to the stimulus side) and the incongruent trials (response contralateral to the stimulus side). The Simon effect corresponds to the lengthening of the reaction time observed in incongruent trials. All the participants first performed a training phase during the familiarization session consisting of a minimum of four blocks of 64 trials. Two additional blocks were performed, if necessary, until the following learning criteria were achieved in one block: (1) intra-block reaction time variability below 25%; (2) inter-blocks reaction time variability with the previous block below 5%; (3) mean reaction time less than 400 ms; and (4) error rate between 3% and 10%.

During the experimental sessions, participants were required to complete six blocks of 64 trials. Participants had to fixate on a white point, positioned in the center of the screen and were required to respond as quickly and accurately as possible by pressing the appropriate response key according to the shape (i.e. square or circle) of a geometric symbol delivered either on the left side or the right side of the fixation point. The distance between the fixation point and the stimulus located either on the right- or the left-side was 7.5 cm. The stimulus-response mapping (e.g. right response for a square and left response for a circle) was counterbalanced across participants. As soon as a response key was pressed or when a delay of 1.5 seconds after the stimulus onset had elapsed without a response, the stimulus was removed from the screen and the next trial began.

Duration-production task. The temporal tasks are useful to dissociate the effect of factors on attention and arousal levels [22], two processes that usually remain amalgamated in most studies.

The duration-production task consists in pressing a button for a time interval learned during a training phase which was performed prior to each experimental session. The training phase consisted of two parts as previously described [22, 25]. For the first 10 trials, a 600 Hz tone sounded for 1100 ms. When the sound ended, a red circle appeared in the center of the screen indicating that participants could reproduce the duration of the sound by pressing the right button as long as the sound lasted. When the participants released the button, an auditory feedback was delivered. Five different feedbacks were used. If the produced interval was correct (less than 7.5% longer or shorter than the target), the feedback "correct" was delivered. If the produced duration was too long or too short (7.5%–22.5% longer or shorter than the target), either the word "too long" or "too short" were delivered. If the duration was excessively long or short (more than 22.5% longer or shorter), the words "much too long" or "much too short" were delivered. After the first 10 training trials, participants performed a second training block in which no additional model of target duration was delivered. During the remaining trials, once the red circle appeared on the screen, participants pressed the key for 1100 ms. As in the 10 first trials, an auditory feedback was delivered after each response. The participants continued until they produced 12 correct durations through 15 successive trials. A maximum of 50 trials was presented. If participants did not reach the criterion before the end of the block, they performed a complete training phase again.

During the experimental phases, participants were required to complete six blocks of 50 trials consisting in pressing the right button for 1100 ms. The participants produced the duration once the red circle appeared on the screen. No feedback on performance was given. One and a half seconds after the release of the

key, the red circle appeared again, indicating that the next trial could be initiated. The performance was evaluated by calculating the variance of produced durations in each condition.

Functional near-infrared spectroscopy (fNIRS). fNIRS is an optical neuroimaging technique which is based on neurovascular coupling to infer changes in neuronal activity [26]. Due to its role in cognitive functions such as attention and decision-making, prefrontal cortex was investigated [27–29]. Moreover, the prefrontal cortices are now recognized as playing a role in postural control [30]. Oxyhemoglobin ([HbO$_2$]) and deoxyhemoglobin ([HHb]) concentration and tissue oxygenation index (TSI) changes in response to the cognitive tasks were measured over left prefrontal cortex using a continuous wave NIRS system (Portalite, Artinis Medical Systems, Einsteinweg, The Netherlands). Total hemoglobin concentration ([HbTot]) was calculated as the sum of [HHb] and [HbO$_2$] and reflected the changes in tissue blood volume within the illuminated area [31, 32]. The left prefrontal cortex NIRS signal was assessed between Fp1 and C3 according to the international 10–20 EEG system. The cortical probe was secured to the skin with double-sided tape and maintained with a headband. Optode positioning was identical during all sessions.

Postural control evaluation

Standing postural control was assessed by analyzing the excursions of the center of pressure (CoP), using a posturographic platform (Feetest 6, Technoconcept, Mane, France) settled in a quiet dedicated room, 1 m away from a clueless white wall. Participants stood on the platform barefoot, their feet placed accorded to the AFP-85 norms [33] (4 cm inter-malleolus distance, with anterior open angle of 30°). To best reproduce the physical constraints faced by alpinists during climbing, participants wore a 10-kg backpack. During the acquisitions, participants were instructed to maintain a quiet and stable erected posture, their arm hanging down freely along their body, and to stay still until the evaluator allowed them to move.

Evaluations were performed eyes opened (two trials, participants were instructed to stare at the white wall) and then closed (two trials). Each trial lasted 30 seconds and trials were interspersed by a fixed 30-second period of rest. Data were recorded with a sampling rate of 40 Hz, and calculated using the Posturewin 4 software. As a measure of standing postural control performance, the amount of sway was evaluated by calculating CoP area (90% confidence ellipse, mm²). To accurately describe the postural control strategies in the different situations, length (mm), *SD* in antero-posterior plane (mm), speed (mm/s) and variance of speed of CoP were also calculated. Romberg Index was calculated (ratio between CoP area recorded eyes closed and CoP area recorded eyes opened) to assess the contribution of vision in the postural control strategy. As an information of energy expenditure required to maintain a stable balance, the length / area ratio (= CoP length / CoP area) was calculated [34].

Sleep recording

Sleep evaluations were performed with a polygraph (Vista O$_2$-Novacore, Paris, France) recording nasal flow, thoracic movements, electrocardiogram and SpO$_2$. Computerized data processing was controlled by one of the experimenter (SB) to obtain the apnea-hypopnea index (AHI) and the oxygen desaturation index (ODI) (defined as a 3% SpO$_2$ drop during ≥10 seconds).

Questionnaires

The LLS was used to evaluate symptoms of AMS by a self-assessment questionnaire (5 items scored between 0 and 3: headache, gastrointestinal disturbance, fatigue, dizziness and sleeping disorders) and a clinical evaluation (3 items scored between 0 and 4: ataxia, dizziness, and functional evaluation) [4]. The 9-point Karolinska sleepiness scale [35] was used to evaluate subjective sleepiness with scores ranging between 1 = very alert and 9 = very sleepy (fighting sleep). Sleep latency (rated subjectively by the participants on a semi-quantitative scale: 1 = <15 minutes, 2 = 15 to 30 minutes, 3 = 30 to 45 minutes and 4 = >45 minutes) and sleep quality (rated subjectively as follows: 1 = superficial, 2 = transitional and 3 = deep) were also evaluated.

Blood sampling and analyses

Venous blood samples were collected at 01:40 am in order to measure the serum concentration of zolpidem. After centrifugation (10 minutes, 2500 rpm), serum was stored at –20°C until biological analysis. Serum zolpidem concentrations were semi-quantitatively evaluated by a reverse-phase liquid chromatography performed on a rapid resolution HPLC system (Agilent 1,200 series) equipped with a SupelcoAscentis C18 column.

Main outcome

The main outcome of this study is the reaction time in the Simon task.

Secondary outcomes

Secondary outcomes are the error rate in the Simon task, the variance of produced durations, postural performances (area, length and speed of CoP, antero-posterior displacement, Romberg index and CoP length/area ratio), sleeping parameters (AHI, ODI, and average SpO$_2$), symptoms (LLS and Karolinska sleepiness scale), sleeping quality (sleep quality and latency self-assessment) and fNIRS parameters (mean TSI and hemoglobin concentration changes in the left prefrontal cortex between rest and blocks of cognitive tests).

Sample size calculation

Power assessment for the primary outcome (Simon task) was based on a minimum expected difference of 10±8% between Zolpidem and placebo, similar to the effect of sleep deprivation previously evaluated by our group [36]. Assuming an α level of 5% and power of 80%, 24 participants were required.

Statistical analysis

Normality of distribution and homogeneity of variances of the main variables were confirmed using a Shapiro-Wilk normality test and the Levene's test, respectively. Intention-to-treat analyses were performed using two-way (altitude × treatment) or three-way (altitude × treatment × congruency for the Simon task) ANOVA with repeated measures for each dependent variable. Post-hoc Tukey's tests were applied to determine a difference between two mean values if the ANOVA revealed a significant

main effect or interaction effect. To handle missing data, we performed multiple imputations by chained equation using predictive mean matching. We imputed 22 datasets to fill in missing values for two patients. For all statistical analyses, a two-tailed alpha level of 0.05 was used as the cut-off for significance. All statistical procedures were performed on Statistica version 10 (Statsoft, Tulsa, OK) and Stata version 15 (Statacorp, College Station, TX). All data are expressed as means ± SD except cognitive outcomes in figures expressed as means ± standard error of the mean (SEM).

Results

Twenty-four participants (eight females) were included in this study and the protocol was completed for 22 participants. Two participants had missing values due to incomplete experiments and were included in the analysis after multiple imputations.

Simon task

Mean reaction times
Altitude exposure had no significant effect on mean reaction times ($p > 0.05$) but increased the Simon effect because the

reaction time in incongruent trials only was lengthened (interaction altitude × congruency, $F = 7.71$, $p < 0.01$; Figure 2).

Zolpidem lengthened mean reaction times both at sea level and at altitude (+25.3 ms, 95% CI [13.3, 37.3]; main treatment effect, $F = 23.52$, $p < 0.001$; interaction treatment × altitude, $F = 0.48$, $p = 0.49$), but the effect was smaller during exercise (interaction treatment × exercise, $F = 5.45$, $p = 0.03$; Figure 2A and B). At altitude at rest, the Simon effect tended to be more pronounced with zolpidem (zolpidem 36.5 ± 4.14 seconds vs. placebo 31.8 ± 2.94 ms) because the effect of zolpidem was greater in incongruent than in congruent trials (interaction treatment × congruency, $F = 3.80$, $p = 0.06$; Figure 2A and B). Zolpidem did not modify the magnitude of the Simon effect at sea level and during exercise (results not shown, all $p > 0.05$).

Error rates
Altitude exposure had no significant effect on mean error rates ($p > 0.05$). Zolpidem increased error rates in incongruent trials and not in congruent trials (interaction treatment × congruency, $F = 6.79$, $p = 0.02$; Figure 2C and D). The effect of zolpidem was similar at sea level and at altitude (interaction treatment × altitude, $F = 0.98$, $p = 0.34$) and at rest and during exercise (interaction treatment × exercise, $F = 0.12$, $p = 0.76$).


Figure 2. Simon task performance measured at rest and during exercise, at sea level and at altitude, following zolpidem or placebo intake. (A) Mean reaction time (RT) at rest; (B) mean RT during exercise; (C) Error rate at rest; (D) Error rate during exercise. CO, congruent trials; IN, incongruent trials. Errors bars represent standard errors of the mean. *Main effect of the treatment ($p < 0.05$), ⁺Effect of the treatment in incongruent trials ($p < 0.05$).

Duration-production task

Temporal variability was increased by zolpidem (+38.4 ms, 95% CI [15.2, 61.6]; main effect of treatment, $F = 16.90$, $p < 0.001$; Figure 3A and B) especially in hypoxia (main effect of altitude, $F = 10.85$, $p = 0.003$; interaction treatment × altitude, $F = 3.46$, $p = 0.07$).

SpO_2, heart rate and NIRS data during cognitive tasks

Altitude decreased SpO_2 and increased heart rate both at rest and during exercise (all $p < 0.05$; Table 1). Altitude had a significant effect on prefrontal cortex TSI responses to cognitive tasks during exercise but not at rest (altitude × exercise interaction, $F = 16.89$, $p < 0.001$ and $F = 11.68$, $p = 0.003$ during the Simon task and the duration production task respectively; Figure 4). At altitude compared to sea level, the prefrontal cortex [HbO_2] increase in response to cognitive tasks was larger at rest and lower during exercise, while the [HHb] reduction was smaller at rest and the [HbTot] increase larger both at rest and during exercise in response to cognitive tasks (Table 1).

Zolpidem had no effect on SpO_2 but increased mean heart rate at rest and during exercise (Table 1). The prefrontal TSI increase in response to cognitive tasks at rest was larger with zolpidem compared to placebo (main treatment effect, $F = 5.75$, $p = 0.03$ and $F = 7.10$, $p = 0.02$ during the Simon task and the duration-production task, respectively; Figure 4). Zolpidem had no effect on prefrontal [HbO_2], [HHb], [HbTot] changes in responses to cognitive tasks (Table 1).

Postural evaluation

Altitude increased the CoP length/area ratio compared to sea level but had no effect on the other postural variables (Table 2).

Zolpidem increased the CoP area, the variation of CoP displacement in antero-posterior plane and decreased the CoP length/area ratio compared to placebo (Table 2). Romberg index was not modified by zolpidem (Table 2). There was no interaction between altitude and treatment (all $p > 0.05$).

Sleep recordings and questionnaires

Altitude increased significantly AHI and ODI and decreased significantly mean SpO_2 and sleep quality (Table 3). Significant altitude effects were also observed on LLS, ataxia, and functional evaluation (Table 3).

There was no effect of zolpidem on AHI, mean SpO_2 and minimal SpO_2 while with zolpidem ODI increased significantly less at altitude (Table 3). Compared to placebo, zolpidem increased significantly sleep quality and decreased sleeping latency (Table 3). Zolpidem increased significantly LLS, sleepiness, dizziness, ataxia, and reduced functional evaluation compared to placebo (Table 3).

Blood sampling

Serum zolpidem concentration was 56 ± 32 ng/ml at high altitude (14 participants had a concentration >50 ng/ml) and 49 ± 29 ng/ml at sea level (nine participants had a concentration >50 ng/ml) with no significant difference between sea level and altitude ($p = 0.28$). Following placebo intake, serum samples were free of zolpidem.

Discussion

The results indicate that at early morning wake-up, 4 hours following 10 mg zolpidem intake, the mean reaction times and the error rate increased in the Simon task as did the temporal variability in the duration-production task. Compared to placebo, zolpidem altered several parameters of postural control such as the CoP area and antero-posterior displacement. Zolpidem improved sleep quality but increased symptoms of AMS, dizziness, and ataxia. Altogether, these results indicate that zolpidem intake induces significant alterations in cognitive and postural


Figure 3. Temporal variability measured at rest and during exercise, at sea level and at altitude, following zolpidem or placebo intake. (A) Variance of the produced durations at rest; (B) variance of the produced durations during exercise. Errors bars represent standard errors of the mean. *Main effect of treatment ($p < 0.05$).

Table 1. Prefrontal cortex oxygenation measured by near-infrared spectroscopy during the cognitive tasks at rest and during exercise, at sea level and at altitude, following zolpidem or placebo administration

	Sea level placebo	Sea level zolpidem	Altitude placebo	Altitude zolpidem	Main treatment effect	Main altitude effect	Interaction altitude × treatment
Simon cognitive test at rest							
$[HbO_2]$ (µM)	0.60 ± 1.02	0.74 ± 1.01	1.07 ± 1.39	1.15 ± 1.45	$F = 0.15; p = 0.70$	$F = 5.28; p = 0.032$	$F = 0.00; p = 0.93$
$[HHb]$ (µM)	-0.31 ± 0.33	-0.42 ± 0.43	-0.08 ± 0.60	-0.19 ± 0.46	$F = 0.72; p = 0.40$	$F = 5.11; p = 0.034$	$F = 0.00; p = 0.99$
$[Hb_{Tot}]$ (µM)	0.28 ± 1.03	0.31 ± 1.19	0.98 ± 1.72	0.96 ± 2.04	$F = 0.00; p = 0.99$	$F = 7.89; p = 0.010$	$F = 0.01; p = 0.94$
Simon cognitive test during exercise							
$[HbO_2]$ (µM)	4.01 ± 2.54	3.75 ± 2.78	3.03 ± 1.95	2.69 ± 2.02	$F = 0.59; p = 0.45$	$F = 8.45; p = 0.008$	$F = 0.02; p = 0.89$
$[HHb]$ (µM)	0.18 ± 0.46	0.23 ± 0.45	0.46 ± 0.94	0.35 ± 1.14	$F = 0.07; p = 0.79$	$F = 1.35; p = 0.26$	$F = 0.45; p = 0.45$
$[Hb_{Tot}]$ (µM)	4.19 ± 2.73	3.98 ± 3.05	3.50 ± 2.50	3.04 ± 2.83	$F = 0.52; p = 0.48$	$F = 3.66; p = 0.069$	$F = 0.11; p = 0.74$
Duration-production task at rest							
$[HbO_2]$ (µM)	0.73 ± 1.34	0.75 ± 1.34	1.19 ± 1.51	1.18 ± 1.24	$F = 0.00; p = 0.99$	$F = 2.86; p = 0.11$	$F = 0.97; p = 0.97$
$[HHb]$ (µM)	-0.37 ± 0.45	-0.52 ± 0.49	-0.07 ± 0.64	-0.21 ± 0.66	$F = 2.21; p = 0.15$	$F = 7.68; p = 0.011$	$F = 0.01; p = 0.96$
$[Hb_{Tot}]$ (µM)	0.36 ± 1.39	0.23 ± 1.56	1.11 ± 1.82	0.97 ± 1.44	$F = 0.20; p = 0.66$	$F = 6.62; p = 0.018$	$F = 0.00; p = 0.98$
Duration-production task during exercise							
$[HbO_2]$ (µM)	5.12 ± 3.02	4.47 ± 3.21	3.07 ± 1.87	3.03 ± 2.18	$F = 0.65; p = 0.43$	$F = 19.44; p < 0.001$	$F = 0.70; p = 0.41$
$[HHb]$ (µM)	0.37 ± 0.67	0.34 ± 0.63	0.60 ± 1.13	0.45 ± 1.35	$F = 0.39; p = 0.54$	$F = 0.67; p = 0.42$	$F = 0.20; p = 0.66$
$[Hb_{Tot}]$ (µM)	5.49 ± 3.35	4.82 ± 3.64	3.67 ± 2.67	3.48 ± 3.25	$F = 0.68; p = 0.42$	$F = 9.38; p = 0.006$	$F = 0.27; p = 0.61$
Arterial oxygenation and heart rate at rest							
SpO_2 (%)	96.2 ± 1.1	96.6 ± 1.4	85.3 ± 2.6	85.7 ± 2.0	$F = 1.39; p = 0.25$	$F = 514.2; p < 0.001$	$F = 0.05; p = 0.83$
Heart rate (bpm)	68.1 ± 8.6	74.7 ± 10.5	78.7 ± 9.3	84.8 ± 12.9	$F = 36.85; p < 0.001$	$F = 39.51; p < 0.001$	$F = 0.04; p = 0.85$
Arterial oxygenation and heart rate during exercise							
SpO_2 (%)	96.4 ± 1.1	96.6 ± 1.4	85.3 ± 2.6	85.7 ± 2.0	$F = 0.36; p = 0.56$	$F = 402.8; p < 0.001$	$F = 2.84; p = 0.11$
Heart rate (bpm)	120.1 ± 14.1	123.1 ± 17.3	120.2 ± 14.0	124.6 ± 18.1	$F = 4.46; p = 0.04$	$F = 0.18; p = 0.67$	$F = 0.31; p = 0.59$

Values are mean ± SD. $[HbO_2]$, change in oxyhaemoglobin concentration; $[HHB]$, change in deoxyhaemoglobin concentration; $[Hb_{Tot}]$, change in total haemoglobin concentration; SpO_2, arterial oxygen concentration.

performance and increased symptoms following early waking-up at high altitude.

Cognitive performance

In the present study, we investigated executive functions which refer to a set of cognitive processes allowing for a flexible behavior adapted to an ever-changing environment. More specifically, we focused on cognitive control and time estimation, continuously involved in any goal-oriented behavior by using two well-established and widely used cognitive tasks, respectively a Simon task and a duration-production task.

Zolpidem increased reaction times during the Simon task, but to a smaller extent during exercise compared to rest. The positive effect of exercise on reaction time tasks performance (faster mean reaction times) has been largely documented [37]. This benefit has been explained by a possible increase in the brain activation level globally improving the information processing at both the sensory and motor levels [38, 39]. Our data have shown that this effect was stronger when participants were under zolpidem, suggesting that physical exercise and zolpidem probably act on the brain activation level, but in an opposite way. We have previously shown that exercise could limit the deleterious impact of sleep deprivation on cognition probably by increasing the nervous system activation state [36]. A similar mechanism may contribute to improved cognitive performance induced by exercise in participants with sleepiness following zolpidem intake. The interaction between zolpidem and congruence was close to significance at 3800 m (*p* = 0.06), that is, the interference (or Simon effect) tended to be larger under zolpidem. Although the Simon effect more closely reflects the

impact of task-irrelevant stimulus feature on response conflict and involves different cognitive processes than the Stroop task, the current results are in agreement with those reported by Pilli et al. [40] reporting the psychotropic effects of zolpidem 1 hour after intake at sea level. This result suggests that the cognitive control at high altitude may be less effective under zolpidem, and more specifically yielded to less inhibition of inappropriate responses.

The temporal variability was affected by both altitude and zolpidem. The interaction between the two factors was close to significance (*p* = 0.07), suggesting that the variability may be increased by zolpidem to a larger extent at altitude. In the psychology of time, an increase in temporal variability is considered to reflect a reduced alertness level [41, 42]. Therefore, the interaction could indicate that zolpidem and altitude can both alter alertness level. This is consistent with the lengthening of mean reaction times observed in the Simon task. If alertness level is lower under zolpidem, the participants will have more difficulties in quickly detecting the stimulus and all subsequent processes will be delayed. Interestingly, the magnitude of zolpidem's effect on the interference control, the lengthening of mean reaction times and the increase of temporal variability is comparable to the magnitude of the difference observed in previous studies when comparing performance of control adult participants and adults diagnosed with attention deficit disorders known to present fluctuations of alertness level [43, 44].

fNIRS measurements during the cognitive tasks were performed in order to provide some insight into the mechanisms associated with the effects of zolpidem on cognitive performance. TSI was affected by zolpidem during both cognitive tasks, with larger increase in response to the cognitive tasks with zolpidem.

Figure 4. Change in prefrontal cortex oxygenation (tissue saturation index, TSI) measured by near-infrared spectroscopy in response to the cognitive tasks at rest and during exercise, at sea level and at altitude, following zolpidem or placebo administration. (A) TSI response to the Simon test at rest; (B) TSI response to the Simon test during exercise; (C) TSI response to the duration-production task at rest; (D) TSI response to the duration-production task during exercise. Errors bars represent standard errors of mean. *Main effect of treatment ($p < 0.05$).

This larger increase in prefrontal cortex oxygenation in response to both cognitive tasks could be interpreted as a greater neurovascular coupling, reflecting increased neuronal activity during cognitive tasks under zolpidem [26]. This result may indicate that a given cognitive task requires a greater neuronal activation under zolpidem. It can be hypothesized that this larger activation of the prefrontal cortex allowed compensating, at least in part, the adverse effects of zolpidem on cognitive performance.

It should be emphasized that the effects of zolpidem on cognitive performance could be explained by cerebral mechanisms involving other areas than the prefrontal cortex which was the only region investigated under the present experimental conditions. Licata et al. [45] have demonstrated by using functional magnetic resonance imaging that zolpidem does not alter prefrontal cortex resting state while it increased BOLD signal in the primary motor cortex, the pre- and post-central gyri, the supplemental motor area, and the basal ganglia.

Postural evaluation

The present results emphasize the deleterious effects of zolpidem on postural control parameters such as the CoP displacement area and the SD of the antero-posterior CoP shifting length.

These results are in accordance with the literature regarding the effects of zolpidem on postural control observed at sea level [15, 16, 46] and suggest that the deleterious effect of the treatment on postural control also occurs at high altitude. The magnitude of the deleterious effects of Zolpidem on postural control parameters such as CoP displacement area and antero-posterior CoP shifting is close to the magnitude of the difference observed in previous studies when comparing postural control in healthy participants and in patients diagnosed with multiple sclerosis, a disabling neurological medical condition related to an increased fall risk [47–49].

From a pathophysiological point of view, zolpidem binds selectively to a gamma-aminobutyric acid(A) receptor (GABA(A)), the ω_1 benzodiazepine receptor predominantly located in the brain and more precisely in cerebellum, hippocampus and globus-pallidus [50]. This receptor is responsible for the hypnotic-sedative effects of benzodiazepine and derivatives, such as zolpidem for instance [51]. The postural control disturbances induced by short-acting hypnotics is therefore probably linked to their sedative-hypnotic effect rather than by the specific muscle-relaxant effect of benzodiazepines [46]. In the study by Nakamura et al. [46], postural sway in hypnotic use was found to be closely correlated with drug concentrations in the blood. Hence, the results underline the deleterious effects of zolpidem

Table 2. Displacement of the center of pressure during the postural evaluation with eyes opened at sea level and at altitude, following zolpidem or placebo administration

	Sea level placebo	Sea level zolpidem	Altitude placebo	Altitude zolpidem	Main treatment effect	Main altitude effect	Interaction altitude × treatment
CoP area (mm^2)	126.5 ± 61.0	240.4 ± 134.4	112.7 ± 57.5	231.7 ± 205.2	$F = 22.42; p < 0.001$	$F = 0.36; p = 0.556$	$F = 0.02; p = 0.905$
Length (mm)	247.5 ± 74.0	262.6 ± 70.6	264.3 ± 74.8	267.8 ± 98.1	$F = 0.69; p = 0.416$	$F = 1.11; p = 0.304$	$F = 0.37; p = 0.549$
Ant-Post (mm)	3.5 ± 1.4	4.7 ± 2.2	3.2 ± 0.9	4.2 ± 2.1	$F = 12.45; p = 0.002$	$F = 1.99; p = 0.173$	$F = 0.06; p = 0.808$
Speed (mm/s)	8.3 ± 2.5	8.8 ± 2.4	8.8 ± 2.5	8.9 ± 3.3	$F = 0.69; p = 0.416$	$F = 1.11; p = 0.304$	$F = 0.37; p = 0.549$
Speed variability (mm^2/s^2)	38.6 ± 34.4	40.8 ± 22.3	39.5 ± 24.5	47.0 ± 42.6	$F = 0.94; p = 0.343$	$F = 0.60; p = 0.449$	$F = 0.32; p = 0.581$
Romberg index	2.2 ± 0.8	2.0 ± 1.1	1.9 ± 0.6	2.0 ± 0.7	$F = 0.01; p = 0.921$	$F = 0.84; p = 0.370$	$F = 0.78; p = 0.386$
Length/ area ratio (mm^{-1})	2.2 ± 0.7	1.5 ± 1.0	2.6 ± 0.8	1.8 ± 1.2	$F = 24.93; p < 0.001$	$F = 6.0; p = 0.023$	$F = 0.08; p = 0.775$

Values are mean ± SD. Ant-Post, SD in antero-posterior plane of CoP displacement length; Romberg index is the ratio between measured surface with eyes closed and eyes opened.

Table 3. Sleep recordings, sleep quality, sleepiness, and symptoms at sea level and at altitude, following zolpidem or placebo administration

	Sea level placebo	Sea level zolpidem	Altitude placebo	Altitude zolpidem	Main treatment effect	Main altitude effect	Interaction altitude × treatment
AHI (events/hour)	5.6 ± 3.9	8.3 ± 6.5	27.0 ± 33.0	22.6 ± 31.0	$F = 0.06; p = 0.805$	$F = 8.98; p = 0.007$	$F = 1.20; p = 0.285$
ODI (events/hour)	2.8 ± 3.8	4.6 ± 5.8	50.4 ± 46.9	28.9 ± 16.7	$F = 4.94; p = 0.039$	$F = 30.66; p < 0.001$	$F = 7.81; p = 0.012$
Mean SpO_2 (%)	94.4 ± 1.7	90.8 ± 16.9	77.4 ± 3.7	77.7 ± 4.1	$F = 0.69; p = 0.42$	$F = 370.93; p < 0.001$	$F = 0.39; p = 0.54$
Minimum SpO_2 (%)	92.8 ± 4.0	87.7 ± 16.7	70.1 ± 5.5	71.0 ± 6.8	$F = 0.22; p = 0.64$	$F = 250.36; p < 0.01$	$F = 1.93; p = 0.18$
Sleep quality	2.0 ± 0.8	2.8 ± 0.4	1.8 ± 0.8	2.3 ± 0.8	$F = 15.59; p < 0.001$	$F = 7.55; p = 0.012$	$F = 0.90; p = 0.355$
Sleep latency	2.6 ± 1.1	1.5 ± 0.6	2.7 ± 1.2	1.9 ± 0.8	$F = 23.16; p < 0.001$	$F = 0.86; p = 0.365$	$F = 0.78; p = 0.389$
Karolinska scale	4.4 ± 1.5	5.5 ± 1.8	4.5 ± 1.7	5.2 ± 1.7	$F = 6.90; p = 0.016$	$F = 0.03; p = 0.872$	$F = 0.96; p = 0.339$
Lake Louise Score	1.0 ± 1.0	3.2 ± 2.8	3.7 ± 2.2	4.6 ± 2.6	$F = 22.20; p < 0.001$	$F = 21.83; p < 0.001$	$F = 0.68; p = 0.418$
Dizziness	0.0 ± 0.2	0.6 ± 0.7	0.3 ± 0.6	0.5 ± 0.8	$F = 11.34; p = 0.003$	$F = 0.13; p = 0.724$	$F = 4.04; p = 0.057$
Ataxia	0.0 ± 0.2	0.5 ± 0.7	0.4 ± 0.6	0.8 ± 0.7	$F = 10.66; p = 0.004$	$F = 6.43; p = 0.019$	$F = 0.21; p = 0.648$
Functional estimation	0.2 ± 0.4	1.0 ± 0.8	0.9 ± 0.4	1.5 ± 0.7	$F = 22.20; p < 0.001$	$F = 21.83; p < 0.001$	$F = 0.68; p = 0.418$

Values are mean ± SD. Dizziness, ataxia, and functional evaluation are clinical assessment of the Lake Louise Score.

on postural control at altitude which may raise security issue for alpinists using hypnotics.

Sleep and symptoms

Our results show that zolpidem intake increases significantly self-reported sleepiness at early awakening in association with clinical observation of greater ataxia, dizziness, and altered functional capacity. These data are in accordance with the literature regarding balance alteration and augmented falling risks after zolpidem intake [52, 53]. The LLS designed to evaluate AMS during altitude exposure is made of non-specific symptoms such as fatigue and dizziness. The LLS was significantly increased under zolpidem both at sea level and at altitude (Table 2). This indicates that zolpidem did not increase AMS per se but rather induced debilitating symptoms both at sea level and at altitude similar to those induced by hypoxia at altitude.

Polygraphic recordings indicated increased AHI, increased desaturations and reduced average SpO_2 level at altitude in accordance with the literature on the effects of high altitude on sleep [1, 3]. Similar to the results of Beaumont et al. [9], there was no impact of zolpidem on AHI at altitude. The decrease in ODI under zolpidem at high altitude may suggest that this medication affects the hypoxemic consequences of nocturnal respiratory perturbations secondary to high altitude exposure. A reduction in the number of hypoxia-reoxygenation events following zolpidem intake could diminish the physiological stress caused by sleep at high altitude. The reason why this index of desaturation is improved by zolpidem with no change in AHI and mean nocturnal SpO_2 has yet to be explained.

Following zolpidem intake, the participants reported an improved sleep quality with a diminished sleeping latency, allowing to overcome at least in part the negative effects of high altitude on sleep. The analysis of the Karolinska score showed that the capacity to stay awake 4 hours after the zolpidem consumption is significantly deteriorated. This effect is critical during sojourn at high altitude with climbing activities, with potential deleterious consequences on the safety of climbers using zolpidem.

Serum concentration of zolpidem

Although zolpidem is considered as a short-acting hypnotic due to its rapid elimination rate, in almost 60% of the blood sample zolpidem concentration was >50 ng/ml 4 hours after drug

intake. This concentration is known to induce cognitive alterations [13] and postural control alterations at sea level [46] and the Food Drug and Administration had recently published recommendations [54] to reduce the risk of presenting concentration >50 ng/ml at wakening.

Conclusions

This randomized, controlled and double-blind study demonstrates the deleterious residual effects of zolpidem intake at altitude following early waking-up as commonly done by alpinists. The cognitive performance was altered as shown by impaired cognitive control and increased reaction times, error rates and temporal variability. These substantial functional alterations could impair the ability to detect stimuli, delay information processing and reduce inhibition of inappropriate responses. Several parameters of postural control were also altered, such as the CoP area and the antero-posterior displacement, emphasizing objective postural control alterations. As expected, zolpidem improved sleep quality and reduced sleep latency, but it also increased symptoms of AMS, dizziness, and ataxia and altered functional evaluation. Altogether, these results indicate that zolpidem intake and early waking-up at altitude are associated with significant alteration in cognitive and postural performance and increased symptoms which may be deleterious for alpinist safety and climbing abilities.

References

1. Ainslie PN, *et al*. Breathing and sleep at high altitude. *Respir Physiol Neurobiol*. 2013;**188**(3):233–256.
2. Bloch KE, *et al*. Sleep at high altitude: guesses and facts. *J Appl Physiol (1985)*. 2015;**119**(12):1466–1480.
3. Windsor JS, *et al*. Sleep disturbance at altitude. *Curr Opin Pulm Med*. 2012;**18**(6):554–560.
4. Roach RC, *et al*. The Lake Louise Acute Mountain Sickness Scoring System. In: Sutton JR, Coates J, Houston CS, eds. *Hypoxia and Molecular Medicine*. Burlington, VT: Queen City Printers; 1993:272–274.
5. Jouanin JC, *et al*. Short half-life hypnotics preserve physical fitness and altitude tolerance during military mountainous training. *Mil Med*. 2009;**174**(9):964–970.
6. Robach P, *et al*. Drug use on mont blanc: a study using automated urine collection. *PLoS One*. 2016;**11**(6):e0156786.
7. Sanger DJ, *et al*. The pharmacology and mechanism of action of zolpidem. *CNS Drug Rev*. 1998;**4**(4):323–340.
8. Beaumont M, *et al*. Effects of zolpidem and zaleplon on sleep, respiratory patterns and performance at a simulated altitude of 4,000 m. *Neuropsychobiology*. 2004;**49**(3):154–162.
9. Beaumont M, *et al*. Zaleplon and zolpidem objectively alleviate sleep disturbances in mountaineers at a 3,613 meter altitude. *Sleep*. 2007;**30**(11):1527–1533.
10. Beaumont M, *et al*. Effect of zolpidem on sleep and ventilatory patterns at simulated altitude of 4,000 meters. *Am J Respir Crit Care Med*. 1996;**153**(6 Pt 1):1864–1869.
11. Terzano MG, *et al*. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. *Drug Saf*. 2003;**26**(4):261–282.
12. Danjou P, *et al*. A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening. *Br J Clin Pharmacol*. 1999;**48**(3):367–374.
13. Farkas RH, *et al*. Zolpidem and driving impairment–identifying persons at risk. *N Engl J Med*. 2013;**369**(8):689–691.
14. Vermeeren A. Residual effects of hypnotics: epidemiology and clinical implications. *CNS Drugs*. 2004;**18**(5):297–328.
15. Boyle J, *et al*. Tolerability, pharmacokinetics and night-time effects on postural sway and critical flicker fusion of gaboxadol and zolpidem in elderly subjects. *Br J Clin Pharmacol*. 2009;**67**(2):180–190.
16. Otmani S, *et al*. Effects of prolonged-release melatonin and zolpidem on postural stability in older adults. *Hum Psychopharmacol*. 2012;**27**(3):270–276.
17. Schulz KF, *et al*.; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *PLoS Med*. 2010;**7**(3):e1000251.
18. Horne JA, *et al*. A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. *Int J Chronobiol*. 1976;**4**(2):97–110.
19. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep*. 1991;**14**(6):540–545.
20. Buysse DJ, *et al*. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. *Psychiatry Res*. 1989;**28**(2):193–213.
21. Simon JR. The effects of an irrelevant directional cue on human information processing. In: Proctor RW, Reeve TG, eds. *Stimulus-Response Compatibility: An Integrated Perspective*. Amsterdam, Netherlands: North-Holland; 1990:31–86.
22. Burle B, *et al*. Dissociation between activation and attention effects in time estimation: implications for internal clock models. *J Exp Psychol Hum Percept Perform*. 2001;**27**(1):195–205.
23. Wasserman K, *et al*. *Principles of Exercise Testing and Interpretation*, 3rd ed. Baltimore, MD: Lippincott; 1999.
24. Fulco CS, *et al*. Maximal and submaximal exercise performance at altitude. *Aviat Space Environ Med*. 1998;**69**(8):793–801.
25. Casini L, *et al*. How does one night of sleep deprivation affect the internal clock? *Neuropsychologia*. 2013;**51**(2):275–283.
26. Tachtsidis I, *et al*. False positives and false negatives in functional near-infrared spectroscopy: issues, challenges, and the way forward. *Neurophotonics*. 2016;**3**(3):031405.
27. Daffner KR, *et al*. The central role of the prefrontal cortex in directing attention to novel events. *Brain*. 2000;**123**(Pt 5):927–939.
28. Miller EK, *et al*. An integrative theory of prefrontal cortex function. *Annu Rev Neurosci*. 2001;**24**:167–202.
29. Suzuki M, *et al*. Prefrontal and premotor cortices are involved in adapting walking and running speed on the treadmill: an optical imaging study. *Neuroimage*. 2004;**23**(3):1020–1026.
30. Mihara M, *et al*. Role of the prefrontal cortex in human balance control. *Neuroimage*. 2008;**43**(2):329–336.

31. Hoshi Y, *et al*. Interpretation of near-infrared spectroscopy signals: a study with a newly developed perfused rat brain model. *J Appl Physiol (1985)*. 2001;**90**(5):1657–1662.

32. Van Beekvelt MC, *et al*. Performance of near-infrared spectroscopy in measuring local O(2) consumption and blood flow in skeletal muscle. *J Appl Physiol (1985)*. 2001;**90**(2):511–519.

33. AFP. *Normes AFP*. Paris, France: AFP; 1985.

34. Gagey PM, *et al*. *Posturologie: Régulation et Dérèglements de la Station Debout*. Paris, France: Masson; 2004.

35. Gamberale F, *et al*. Behavioral and psychophysiological effects of the physical work environment. Research strategies and measurement methods. *Scand J Work Environ Health*. 1990;**16** (Suppl 1):5–16.

36. Temesi J, *et al*. Does central fatigue explain reduced cycling after complete sleep deprivation? *Med Sci Sports Exerc*. 2013;**45**(12):2243–2253.

37. McMorris T, *et al*. *Exercise and Cognitive Function*. Chichester, UK: Wiley, J. & Sons; 2009.

38. Davranche K, *et al*. Information processing during physical exercise: a chronometric and electromyographic study. *Exp Brain Res*. 2005;**165**(4):532–540.

39. Davranche K, *et al*. Physical exercise facilitates motor processes in simple reaction time performance: an electromyographic analysis. *Neurosci Lett*. 2006;**396**(1):54–56.

40. Pilli R, *et al*. A computerized Stroop test for the evaluation of psychotropic drugs in healthy participants. *Indian J Psychol Med*. 2013;**35**(2):180–189.

41. Allan LG. Time, action, and cognition: towards bridging the gap. In: Macar F, Pouthas V, Friedman W, eds. *The Internal Clock Revisited*. Dordrecht, Netherlands: Kluwer Academic; 1992:191–202.

42. Droit-Volet S. Alerting attention and time perception in children. *J Exp Child Psychol*. 2003;**85**(4):372–384.

43. Suarez I, *et al*. Deciphering interference control in adults with ADHD by using distribution analyses and electromyographic activity. *Acta Psychol (Amst)*. 2015;**159**:85–92.

44. Suarez I, *et al*. The cognitive structure of time estimation impairments in adults with attention deficit hyperactivity disorder. *Cogn Neuropsychol*. 2013;**30**(4):195–207.

45. Licata SC, *et al*. The hypnotic zolpidem increases the synchrony of BOLD signal fluctuations in widespread brain networks during a resting paradigm. *Neuroimage*. 2013;**70**:211–222.

46. Nakamura M, *et al*. Temporal changes in postural sway caused by ultrashort-acting hypnotics: triazolam and zolpidem. *ORL J Otorhinolaryngol Relat Spec*. 2005;**67**(2):106–112.

47. Anbarian M, *et al*. A comparison of linear and nonlinear stability parameters in different clinical forms of multiple sclerosis. *Eur Rev Aging Phys Act*. 2015;**12**:9.

48. Comber L, *et al*. Postural control deficits in people with multiple sclerosis: a systematic review and meta-analysis. *Gait Posture*. 2018;**61**:445–452.

49. Giannì C, *et al*. A systematic review of factors associated with accidental falls in people with multiple sclerosis: a meta-analytic approach. *Clin Rehabil*. 2014;**28**(7):704–716.

50. Sieghart W. Benzodiazepine receptors: multiple receptors or multiple conformations? *J Neural Transm*. 1985;**63**(3–4):191–208.

51. Rudolph U, *et al*. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. *Nature*. 1999;**401**(6755):796–800.

52. Allain H, *et al*. Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review. *Drugs Aging*. 2005;**22**(9):749–765.

53. Frey DJ, *et al*. Influence of zolpidem and sleep inertia on balance and cognition during nighttime awakening: a randomized placebo-controlled trial. *J Am Geriatr Soc*. 2011;**59**(1):73–81.

54. FDA. Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem. 2013. https://www.fda.gov/. Accessed February 8, 2018.